o-demethyltramadol has been researched along with Benign Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hiraide, T; Kawakami, J; Naito, T; Sato, H; Tanaka, H; Yamada, Y | 1 |
| Leppert, W; Mikolajczak, P | 1 |
2 other study(ies) available for o-demethyltramadol and Benign Neoplasms
| Article | Year |
|---|---|
Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.
Topics: Administration, Oral; Aged; Analgesics, Opioid; Asian People; C-Reactive Protein; Cancer Pain; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Female; Genotype; Humans; Interleukin-6; Male; Middle Aged; Neoplasms; Time Factors; Tramadol | 2018 |
Analgesic effects and assays of controlled-release tramadol and o-desmethyltramadol in cancer patients with pain.
Topics: Aged; Aged, 80 and over; Analgesia; Analgesics, Opioid; Codeine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasms; Pain; Pain Measurement; Tramadol | 2011 |